These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 22993352)
1. Hyperfractionated radiotherapy with concurrent docetaxel for advanced head and neck cancer: a phase II study. Karasawa K; Matsumoto F; Ito S; Oba S; Furuya T; Hirowatari H; Izawa H; Ito K; Sasai K Anticancer Res; 2012 Sep; 32(9):4013-8. PubMed ID: 22993352 [TBL] [Abstract][Full Text] [Related]
2. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer. Allal AS; Zwahlen D; Becker M; Dulguerov P; Mach N Cancer J; 2006; 12(1):63-8. PubMed ID: 16613664 [TBL] [Abstract][Full Text] [Related]
3. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475 [TBL] [Abstract][Full Text] [Related]
4. Phase II trial: concurrent radio-chemotherapy with weekly docetaxel for advanced squamous cell carcinoma of head and neck. Biete Solà A; Marruecos Querol J; Calvo Manuel FA; Verger Fransoy E; Rovirosa Casino A; Grau de Castro JJ; de Las Heras González M; Ramos Aguerri A; Palacios Eito A; Veiras Candal C; Solano López MV Clin Transl Oncol; 2007 Apr; 9(4):244-50. PubMed ID: 17462977 [TBL] [Abstract][Full Text] [Related]
5. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity]. Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261 [TBL] [Abstract][Full Text] [Related]
6. Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer. Suzuki M; Nishimura Y; Nakamatsu K; Kanamori S; Koike R; Kawamoto M; Mori K Jpn J Clin Oncol; 2003 Jun; 33(6):297-301. PubMed ID: 12913084 [TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. Tsao AS; Garden AS; Kies MS; Morrison W; Feng L; Lee JJ; Khuri F; Zinner R; Myers J; Papadimitrakopoulou V; Lewin J; Clayman GL; Ang KK; Glisson BS J Clin Oncol; 2006 Sep; 24(25):4163-9. PubMed ID: 16943532 [TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up. Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029 [TBL] [Abstract][Full Text] [Related]
9. Concurrent weekly docetaxel and hyperfractionated radiotherapy for advanced head and neck cancer. Matsumoto F; Karasawa K; Itoh S; Toda M; Haruyama T; Furukawa M; Ikeda K Anticancer Res; 2006; 26(5B):3781-6. PubMed ID: 17094401 [TBL] [Abstract][Full Text] [Related]
10. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Kovács AF; Mose S; Böttcher HD; Bitter K Strahlenther Onkol; 2005 Jan; 181(1):26-34. PubMed ID: 15660190 [TBL] [Abstract][Full Text] [Related]
11. Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer. Karasawa K; Shinoda H; Katsui K; Seki K; Kohno M; Hanyu N; Nasu S; Muramatsu H; Maebayashi K; Mitsuhashi N; Yoshihara T Anticancer Res; 2002; 22(6B):3785-8. PubMed ID: 12552993 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin. Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma. Nakahara S; Takenaka Y; Ogawa K; Nishiike S; Yamamoto Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Yoshii T; Tomiyama Y; Inohara H Int J Clin Oncol; 2016 Dec; 21(6):1030-1037. PubMed ID: 27306220 [TBL] [Abstract][Full Text] [Related]
14. Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study). Barnadas A; Mesía R; Majem M; Galiana R; López-Pousa A; de Vega JM; Margelí M; Valentí V; Anglada L; Lloansí A; Arellano A Clin Transl Oncol; 2011 Apr; 13(4):254-60. PubMed ID: 21493186 [TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Fujii M; Tsukuda M; Satake B; Kubota A; Kida A; Kohno N; Okami K; Inuyama Y; Int J Clin Oncol; 2004 Apr; 9(2):107-12. PubMed ID: 15108042 [TBL] [Abstract][Full Text] [Related]
16. A Phase II multi-institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-risk postoperative head and neck cancer patients. Willey CD; Murphy BA; Netterville JL; Burkey BB; Shyr Y; Shakhtour B; Kish B; Raben D; Chen C; Song JI; Kane MA; Cmelak AJ Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1323-31. PubMed ID: 17289289 [TBL] [Abstract][Full Text] [Related]
17. Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer. Yokota T; Onoe T; Ogawa H; Hamauchi S; Iida Y; Kamijo T; Suda T; Yurikusa T; Nishimura T; Yasui H; Onitsuka T Jpn J Clin Oncol; 2015 Feb; 45(2):183-8. PubMed ID: 25420692 [TBL] [Abstract][Full Text] [Related]